• Vaccine Name: Brucella abortus rough-strain outer membrane–peptidoglycan complex subunit vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009063
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• Host Species as Laboratory Animal Model: Bos taurus (cattle)
• Antigen: outer membrane-peptidoglycan complex (OM-PG)
• Adjuvant: commercial adjuvant
• Preparation: OM-PG preparations emulsified in a commercial adjuvant; doses ranged from 400 to 8000 micrograms; administered in single or two inoculations. (Smith et al, 1990)
• Description: The OM-PG from rough strains of Brucella abortus was tested for its ability to induce lymphocyte responsiveness in cattle. Efficacy: Frequency of lymphocyte responsiveness increased with dose and with two inoculations compared to single inoculations; OM-PG from a rough transposon mutant induced comparable responsiveness to that from a spontaneous rough mutant; differences in lymphocyte specificity compared to strain 19 vaccine. Immune response: Induction of lymphocyte proliferation responses in cattle; lymphocytes stimulated by OM-PG had different specificities than those stimulated by strain 19 vaccination. (Smith et al, 1990)

Cattle Response

• Vaccination Protocol: Immunization of heifers with varying doses and schedules of OM-PG; lymphocyte proliferation assays in vitro to assess lymphocyte responsiveness. (Smith et al, 1990)
• Immune Response: Induction of lymphocyte proliferation responses in cattle; lymphocytes stimulated by OM-PG had different specificities than those stimulated by strain 19 vaccination. (Smith et al, 1990)
• Efficacy: Frequency of lymphocyte responsiveness increased with dose and with two inoculations compared to single inoculations; OM-PG from a rough transposon mutant induced comparable responsiveness to that from a spontaneous rough mutant; differences in lymphocyte specificity compared to strain 19 vaccine. (Smith et al, 1990)
• Description: Immunization of heifers with varying doses and schedules of OM-PG; lymphocyte proliferation assays in vitro to assess lymphocyte responsiveness. (Smith et al, 1990)